A Phase II study of S-1 plus oral leucovorin in heavily treated metastatic colorectal cancer patients.

ABSTRACT:

Purpose

Fewer treatment options are available for refractory metastatic colorectal cancer (mCRC). In early trials, S-1 monotherapy was effective for mCRC patients after chemotherapy failure and its combination with oral leucovorin therapy offers promising results in untreated mCRC. Hence, we conduct a Phase II trial to assess the efficacy of S-1 plus oral leucovorin (SL) in refractory mCRC that progressed after multiple prior standard therapies.

Methods

In this open-label, single-arm study, we enrolled the refractory mCRC patients who received fluoropyrimidine, oxaliplatin, and irinotecan treatment and at least one targeted therapy previously. The doses of SL were 40-60 and 30 mg twice daily separately. They were administered for 7 days in a 2-week cycle. Treatment was conti

SUBMITTER: Hsu HC 

PROVIDER: S-EPMC6252780 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature